Ligand id: 8256


Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 115.22
Molecular weight 340.16
XLogP -0.15
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Phase I clinical trial NCT01777243 is currently recruiting patients with systemic amyloidosis to assess treatment with dezamizumab (anti-SAP mAb) in combination with CPHPC.
Mechanism Of Action and Pharmacodynamic Effects
CPHPC effectively reduces circulating and visceral SAP in a mouse model of systemic AA amyloidosis (transgenics expressing human SAP) [1] and in humans [2] by acting as a competitive inhibitor of SAP binding to amyloid fibrils. CPHPC-bound SAP is rapidly cleared by the liver [3-4]. Unfortunately, residual SAP bound to visceral amyloid plaques persists even with prolonged CPHPC exposure [1]. CPHPC combined with immunotherapy using mAb GSK2398852 is predicted to clear the persistent SAP in amyloid fibrils.